Streetbeat News

Stock Prices

CORZ

High-rolling investors have shown a bullish sentiment on Core Scientific (NASDAQ:CORZ) through significant options trading activity. Benzinga's options scanner identified 16 trades, with 75% being bullish. The price range of interest is between $9.5 and $14.5. Analysts have mixed ratings, with price targets ranging from $13 to $20.

Portfolio Pulse from Benzinga Insights

July 29, 2024 | 2:02 pm

FCF

Four analysts have provided mixed ratings for First Commonwealth (NYSE:FCF) over the past quarter, with an average 12-month price target of $18.0, up 14.29% from the previous $15.75. Analysts have raised their price targets, reflecting positive sentiment towards the company's financial performance.

Portfolio Pulse from Benzinga Insights

July 29, 2024 | 2:01 pm

U

In the last three months, 9 analysts have published ratings on Unity Software (NYSE:U), with a mix of bullish and bearish perspectives. The average 12-month price target is $26.61, a decrease from the previous $27.62. Key analysts have adjusted their ratings and price targets, reflecting changing market dynamics and company performance. Unity Software faces challenges with declining revenue, low net margin, and high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

July 29, 2024 | 2:01 pm

CMG

Chipotle Mexican Grill (NYSE:CMG) has significantly outperformed the market over the past 15 years, delivering an average annual return of 24.21%. A $1000 investment in CMG 15 years ago would be worth $26,357.89 today. The article highlights the power of compounded returns.

Portfolio Pulse from Benzinga Insights

July 29, 2024 | 2:01 pm

ROP

Roper Technologies (NASDAQ:ROP) has outperformed the market over the past decade, delivering an average annual return of 14.29%. A $1000 investment in ROP 10 years ago would be worth $3,771.16 today. The article highlights the power of compounded returns.

Portfolio Pulse from Benzinga Insights

July 29, 2024 | 2:00 pm

CNC

In the past three months, 13 analysts have provided ratings for Centene (NYSE:CNC), with a mix of bullish, somewhat bullish, and indifferent perspectives. The average 12-month price target has decreased from $93.17 to $87.46. Analysts have recently adjusted their ratings and price targets, reflecting changing market dynamics and company performance. Centene has shown positive revenue growth and strong profitability metrics but faces challenges in debt management.

Portfolio Pulse from Benzinga Insights

July 29, 2024 | 2:00 pm

PALI

Palisade Bio shares are trading higher after the company completed a microbiome study confirming bacterial enzymes for local bioactivation of PALI-2108.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 1:49 pm

NLSP

NLS Pharmaceutics shares are trading higher following the announcement of a merger where Kadimastem will become a wholly owned subsidiary of NLS.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 1:48 pm

LIPO

Lipella Pharmaceuticals shares are trading higher after the company announced it commenced its Phase 2a trial for LP-310 in Oral Lichen Planus.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 1:46 pm

VTYX

Ventyx Biosciences shares are trading lower after the company announced its Phase 2 trial of VTX958 for Crohn's disease did not meet its primary endpoint.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 1:46 pm